| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2018: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
Hematopoietic stem cells are injured by auto immune cells in aplastic anemia. Hematopoietic stem cells escape the attack of T cells with various way to keep the production of blood cells as that way could directly effects on the hematopoiesis. The purpose of that research is that each clone could have the different ability of hematopoiesis in the situation of recovery. To clarify that difference, we set up mouse model that have human hematopoiesis by transplanted with hematopoietic stem cells derived from iPS cells. We found that the hematopoietic stem cells with specific phenotype have the advantage ability of hematopoiesis better than others, resulting in the specific clone contribute the hematopoiesis in the recovery situation with immune suppressive therapy.
|
